Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H27N7O3S2 |
| Molecular Weight | 513.636 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(=O)(=O)N1CCN(CC2=CC3=C(S2)C(=NC(=N3)C4=CC=CC5=C4C=NN5)N6CCOCC6)CC1
InChI
InChIKey=LHNIIDJUOCFXAP-UHFFFAOYSA-N
InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)
| Molecular Formula | C23H27N7O3S2 |
| Molecular Weight | 513.636 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pictilisib is an oral potent inhibitor of class I PI3K with nanomolar activities against p110alpha, p110beta, p110delta, and p110gamma. The drug was developed for the treatment of solid tumors and reached phase II in patients with breast cancer and lung carcinoma, however its development was terminated.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.52 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/25370471 |
330 mg single, oral dose: 330 mg route of administration: Oral experiment type: SINGLE co-administered: |
PICTILISIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
19.4 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/25370471 |
330 mg single, oral dose: 330 mg route of administration: Oral experiment type: SINGLE co-administered: |
PICTILISIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
15.7 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/25370471 |
330 mg single, oral dose: 330 mg route of administration: Oral experiment type: SINGLE co-administered: |
PICTILISIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| High-throughput screening compatible cell-based assay for interrogating activated notch signaling. | 2009 Feb |
|
| Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. | 2009 Jul |
|
| Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. | 2009 May 5 |
|
| Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. | 2010 Apr |
|
| Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. | 2010 Feb 1 |
|
| Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. | 2010 Jul 15 |
|
| Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. | 2010 Nov 24 |
|
| Effects of nominally selective inhibitors of the kinases PI3K, SGK1 and PKB on the insulin-dependent control of epithelial Na+ absorption. | 2010 Oct |
|
| Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer. | 2010 Sep 8 |
|
| Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. | 2011 Mar 29 |
|
| Comprehensive analysis of kinase inhibitor selectivity. | 2011 Oct 30 |
|
| PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells. | 2012 |
|
| Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection. | 2012 |
|
| Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. | 2012 Aug |
|
| Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. | 2012 May |
|
| Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. | 2012 May 17 |
|
| Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice. | 2012 Oct |
|
| Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. | 2013 Feb 1 |
|
| GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death. | 2013 Feb 1 |
|
| Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. | 2013 Jan |
|
| A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. | 2013 Nov |
|
| The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. | 2014 Jan 16 |
|
| Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs. | 2015 Jun |
Sample Use Guides
Patients with breast cancer receive paclitaxel (90 mg/m2 weekly for 3 weeks in every 28-day cycle) with 260 mg pictilisib (daily on days 1-5 every week).
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:16:48 GMT 2025
by
admin
on
Mon Mar 31 20:16:48 GMT 2025
|
| Record UNII |
ICY00EMP8P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID40241930
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
DB11663
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
ICY00EMP8P
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
9417
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
CHEMBL521851
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
100000175029
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
SUB120770
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
m11673
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
957054-30-7
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
C165479
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
17755052
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY | |||
|
YY-114
Created by
admin on Mon Mar 31 20:16:48 GMT 2025 , Edited by admin on Mon Mar 31 20:16:48 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
